ScholarWorks@Hanyang University: Choi, Chan Bum

Detailed Information

Choi, Chan Bum (최찬범)

서울 의과대학 (DEPARTMENT OF INTERNAL MEDICINE)

Research Area: 류마티스내과

Tel 02-2290-9208
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Rheumatoid arthritis:27||Systemic lupus erythematosus:5||systemic lupus erythematosus:5||Safety:5||rheumatoid:4||Interstitial lung disease:4||Arthritis:4||polymorphism:4||Korea:4||rheumatoid arthritis:3||arthritis:3||TNF inhibitor:3||Prevalence:3||Rheumatoid:3||Discordance:2||RHEUMATOID ARTHRITIS:2||s disease:2||Etanercept:2||Incidence:2||TNF blocker:2||Persistence:2||Early diagnosis:2||tuberculin skin test:2||genetic:2||Latent tuberculosis:2||Risk factors:2||Comorbidity:2||latent tuberculosis infection:2||Mortality:2||Tumor necrosis factor inhibitor:2||SLE:2||SNP:2||Prognosis:2||Cohort:2||nephritis:2||Osteoarthritis:2||DAS28:2||ankylosing spondylitis:2||Osteoporosis:2||Biosimilar:2||Dermatomyositis:1||Dermatomyositis/polymyositis:1||Diagnosis:1||Disease activity index:1||Disease activity score:1||Drug efficacy:1||Drug persistency:1||Drug retention rate:1||EQ5D:1||ESR:1||Effectiveness:1||Elderly:1||Enrollment:1||Eosinophilic granulomatosis with polyangiitis:1||Epidemiology:1||Fatigue:1||Fracture:1||Fractures:1||Frequency:1||Gastrointestinal diseases:1||Gastrointestinal risk factors:1||Genetic risk score:1||Glucosamine:1||Gout:1||HAQ:1||HAQDI:1||HLADRB1:1||HOUSEHOLD:1||Hemorrhage:1||Hypouricemia:1||INTERFERON REGULATORY FACTOR 5:1||Incidence rate:1||Inflammation:1||Infliximab:1||Internet:1||Intestine:1||Isoniazid:1||KOREA:1||Korean:1||Korean National Health Insurance reimbursement criteria:1||LBEC0101:1||LYN:1||Lung:1||Lupus erythematosus, Systemic:1||Lupus nephritis:1||MALIGNANCY:1||MERTK:1||MORTALITY:1||Malignancy:1||Mapping:1||Matrix metalloproteinase:1||Medical records:1||Medication persistence:1||Medication practices:1||Microscopic polyangiitis:1||Multicenter clinical trial:1||Nonsteroidal antiinflammatory agents:1||Osteomyelitis:1||POLYMORPHISM:1||Pain:1||Patient global assessment:1||Peripheral arterial disease:1||Peripheral blood stem cell transplantation:1||Physician global assessment:1||Pneumomediastinum:1||Polymyalgia Rheumatica:1||Polymyositis:1||Pregnancy:1||Psoriatic arthritis:1||Publication:1||Pulse wave velocity:1||Quality of life:1||QuantiFERONTB Gold InTube test:1||QuantiFERONTB gold in tube test:1||RA:1||Randomized clinical trials:1||Registries:1||Registry:1||Remission:1||Retention:1||Rheumatic diseases:1||Rheumatology:1||Risk:1||SEX:1||SKI306X:1||SYSTEMIC LUPUS ERYTHEMATOSUS:1||Self report:1||Seropositive rheumatoid arthritis:1||Sleep:1||Spondylarthropathies:1||Spondylitis:1||Spondylitis, Ankylosing:1||Spondyloarthropathies:1||Still disease:1||Switch:1||Synovial Fluid:1||Systemic scleroderma:1||TNF inhibitors:1||TNF��:1||TNFalpha blockers:1||TNFblocker:1||TNFα:1||TNFRFc Fusion Protein:1||Tolllike rececptor 4:1||Total hip replacementin:1||Treatment response:1||Tuberculosis:1||Uric acid:1||Utility:1||Validation Studies:1||Validation study:1||Vasculitis:1||acetaminophen:1||active:1||acutephase protein:1||antirheumatic agents:1||association:1||autoimmune diseases:1||bioinformatics:1||biologic agent:1||biologic therapy:1||biological therapy:1||classification:1||clinical aspects:1||cohort study:1||connective tissue disease:1||corticosteroid:1||disease duration:1||etanercept:1||genetics:1||haematological disorder:1||infliximab:1||interferongamma release assay:1||leucopenia:1||lupus nephritis:1||males:1||medical communication aid:1||mesenchymal stem cell:1||multitarget therapy:1||mycophenolate mofetil:1||n3 polyunsaturated fatty acids:1||normal:1||organ damage:1||osteoarthritis:1||p21:1||patient decisionmaking tool:1||prospective study:1||pulmonary hypertension:1||randomized controlled trial:1||rheumatic disease:1||severity:1||shared decisionmaking:1||statistics:1||survival:1||systemic sclerosis:1||tactolimus:1||toxicity:1||tramadol:1||transcriptome:1||treatment:1||tuberculosis:1||tumor necrosis factor inhibitor:1||vasculitis:1||Abatacept:1||waf1:1||Abstract:1||Adalimumab:1||Aggrecanase:1||Algorithm:1||Amino acid:1||Anklebrachial index:1||Ankylosing:1||Ankylosing spondylitis:1||AntiTNF drugs:1||Antineutrophil cytoplasmic antibody:1||Antineutrophil cytoplasmic antibodyassociated vasculitis:1||Antineutrophil cytoplasmic antibody:1||Aortic valve insufficiency:1||Arterial stiffness:1||Asia:1||Associated factors:1||Behçet&apos:1||Behcet&apos:1||Biologic DMARDs:1||Biological products:1||Bone Mineral Density:1||Bone turnover:1||CDKN1A:1||COMPLEMENTARY AND ALTERNATIVE MEDICINE:1||CRP:1||Cartilage:1||Caspase1:1||Cerebrocardiovascular disease:1||Chondroitin:1||ChurgStrauss syndrome:1||Claims data:1||Clinical Effectiveness:1||Clinical characteristics:1||Cohort studies:1||Comorbidities:1||Copy number variations:1||DEPRESSION:1||DMARDs:1||Death:1||

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE